MEI Pharma, Inc.
MEI Pharma, Inc. (MEIP) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
meip · stock forecast · 18 analysts (3M) · FMP · updated Mar 10, 2026
Analyst Rating & Consensus
Based on 18 Wall Street analysts in the past 3 months
Buy
18 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$0.00
Consensus
$0.00
+0.0% upside
Low
$0.00
Median: $0 · Last Close: $2.60
Short-Term Price Prediction
Low ActivityAlgorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-10 | $2.52 | ↓ 3.02% |
1-day model range: $2.44–$2.61. Peak: $2.61 (-3.02%).
Long-Term Stock Price Prediction
Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031
| Year | Avg Price | Change |
|---|---|---|
| 2027 | — | -37.0% |
| 2028 | — | -48.6% |
| 2029 | — | -53.4% |
| 2030 | — | -55.5% |
| 2031 | — | -56.5% |
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Insufficient Trading Activity — Sentiment Signals Disabled
This stock has very low trading volume (ZOMBIE condition). Sentiment analysis requires sufficient price action. RSI and MACD values below are still shown for reference.
Moving Averages · MEIP · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2024-07-23 | Laidlaw & Co. | Downgrade ↓ | Buy→Hold |
| 2024-04-12 | Stifel | Maintains | Hold→Hold |
| 2024-02-14 | Stifel | Maintains | Hold→Hold |
| 2023-09-27 | Stifel | Maintains | Hold→Hold |
| 2023-05-23 | Brookline Capital | Maintains | Buy→Buy |
| 2023-05-12 | Stifel | Maintains | Hold→Hold |
| 2023-02-13 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2023-02-08 | Jefferies | Downgrade ↓ | Hold→Underperform |
| 2022-12-06 | BTIG | Downgrade ↓ | Buy→Neutral |
| 2022-12-06 | Truist Securities | Downgrade ↓ | Buy→Hold |
Wall Street analysts have recently issued updated ratings on MEI Pharma, Inc. (MEIP) stock. Of the recent 36 rating actions, 2 were upgrades and 11 were downgrades. 18 analysts currently cover MEIP.
Analyst Recommendation Trends
MEIP analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 0 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$65M
↑ 161.2% YoY
Revenue Next Year
$6M
↓ 90.4% YoY
EPS This Year
$3.62
EPS Next Year
$-6.28
↓ 273.5% YoY
EPS ForecastReported vs Estimated
Analysts forecast MEIP EPS of $3.62 for the current fiscal year, based on estimates from 2 analysts. The MEIP revenue forecast is $65M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The MEIP stock forecast is supported by two independent data sources: analyst consensus ratings from 18 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus MEIP price target is $0.00 (+0.0% upside), with an analyst consensus of Buy.
The MEIP short-term stock prediction for tomorrow is $2.52 (-3.02%). The MEIP stock prediction for 2030 projects a range of $1–$1.
MEI Pharma, Inc. trades on NASDAQ under the ticker MEIP. The MEIP stock outlook for 2027 is broadly positive, supported by a Buy consensus among 56% of covering analysts.
Frequently asked questions
MEIP forecast · 8 questionsAccording to 18 Wall Street analysts, the average 12-month MEIP price target is $0.00, with a high forecast of $0.00 and a low of $0.00. The median price target is shown in the chart above when available. This implies +0.0% potential upside from the current price of $2.60.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.